Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

spotlight

October 14, 2014

bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy

Read More

September 2, 2014

bluebird bio to Present at Morgan Stanley Global Health Care Conference

Read More

August 12, 2014

bluebird bio Reports Fiscal Second quarter 2014 Financial Results

Read More

August 5, 2014

bluebird bio to Present at Two Upcoming Health Care Conferences

Read More

July 16, 2014

bluebird bio Appoints Mark Vachon to its Board of Directors

Read More